* "Cytotoxic Activity of N-Chlorotaurine on Acanthamoeba spp," Antimicrobial Agents and Chemotherapy. (Furnkranz, U et al. Antimocrob. Agents Chemother.2008;52:470-476).
About Pathogenics, Inc.
Pathogenics, Inc. (PTGN.PK) is a biopharmaceutical company focused on developing its proprietary formulations of N-Chlorotaurine (NCT) for the treatment or prevention of infections. After NCT kills a pathogen, the agent quickly breaks down into natural substances already found in the human body, and therefore it is likely to be extremely safe, non-toxic and hypoallergenic. Unlike antibiotics, the way NCT kills pathogens prevents development of drug resistance. NCT has successfully completed Phase II studies for several topical and body cavity infections. For more information, visit the company's website at http://www.pathogenics.com
About OPKO Health, Inc.
Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III trial after successfully completing Phase II trials for wet age-related macular degeneration and diabetic macular edema. OPKO is developing a pipeline of novel agents for ophthalmic diseases and markets innovative diagnostic imaging systems that complement the company's therapeutic products. For more information visit the company's website at http://www.opko.com.
This press release contains "forward-looking statements," as that term
is defined under the Private Securities Litigation Reform Act of 1995
(PSLRA), which statements may be identified by words such as "expects,"
"plans," "projects," "will," "may," "anticipates," "believes," "should,"
"intends," "estimates," and other wo
|SOURCE OPKO Health, Inc.|
Copyright©2008 PR Newswire.
All rights reserved